Paper Details

  1. Home
  2. Paper Details

Late intensification with POMP chemotherapy prolongs survival in acute myelogenous leukemia--results of a Southwest Oncology Group study of rubidazone versus adriamycin for remission induction, prophylactic intrathecal therapy, late intensification, and levamisole maintenance.

Author: AthensJ W, BalcerzakS P, ColtmanC A, CostanziJ J, DabichL, GumbartC, HeadD R, KopeckyK J, MorrisonF S, SaikiJ H

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Overview

A study of 611 patients with acute myelogenous leukemia (AML) compared different treatment strategies. The study found no difference in remission rates between rubidazone and adriamycin for induction therapy. Prophylactic intrathecal therapy with cytosine arabinoside did not improve outcomes. However, patients who received late intensification therapy with POMP after 9 months of remission had better survival and disease-free survival compared to those who did not. Maintenance therapy with levamisole after 12 months of remission did not impact survival or disease-free survival.
Paper Details　
Original Abstract of the Article :
Between August 1978 and September 1982, 642 patients with newly diagnosed acute myelogenous leukemia (AML) were entered onto a Southwest Oncology Group Study which addressed four questions. (i) What is the comparative utility of rubidazone versus adriamycin in remission induction? (ii) What is the r...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/1625490

データ提供：米国国立医学図書館（NLM）

Late Intensification with POMP Chemotherapy: A Lifeline for AML Patients

The field of [acute myelogenous leukemia (AML)] treatment is constantly evolving, and researchers are tirelessly searching for new ways to improve patient outcomes. This study focuses on the impact of [late intensification] with [POMP chemotherapy] on the survival of [AML patients]. The researchers conducted a large-scale clinical trial investigating the effectiveness of different treatment strategies and found that [late intensification] with [POMP chemotherapy] significantly improved both overall survival and disease-free survival rates in patients who achieved complete remission. These findings provide valuable insights for the management of this challenging disease.

A Powerful Strategy for Prolonging Survival

This study suggests that [late intensification] with [POMP chemotherapy] can be a game-changer for [AML patients] who have achieved complete remission. The results show a clear and statistically significant improvement in survival rates, suggesting that this approach can help extend the lives of these patients. These findings are a testament to the relentless pursuit of better treatments in the field of [hematological malignancies].

Hope on the Horizon for AML Patients

The successful implementation of [late intensification] with [POMP chemotherapy] provides a ray of hope for [AML patients] battling this aggressive disease. This research is a vital step in the quest for more effective treatments that can lead to longer and healthier lives for these patients.

Dr.Camel's Conclusion

Just like a camel who adapts to the harsh conditions of the desert, AML patients must also find ways to navigate the challenges of their disease. This study, a beacon in the vast landscape of cancer research, offers a new strategy for battling AML. The findings suggest that late intensification with POMP chemotherapy can be a valuable tool in the fight against this disease, providing hope for a brighter future for those who face it.

Date :
  1. Date Completed 1992-08-10
  2. Date Revised 2017-11-16
Further Info :

Pubmed ID

1625490

DOI: Digital Object Identifier

1625490

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.